2,614
Views
3
CrossRef citations to date
0
Altmetric
Research Paper

Highly potent inhibitors of cathepsin K with a differently positioned cyanohydrazide warhead: structural analysis of binding mode to mature and zymogen-like enzymes

, , , , , , , , , & show all
Pages 515-526 | Received 30 Nov 2021, Accepted 27 Dec 2021, Published online: 11 Feb 2022
 

Abstract

Cathepsin K (CatK) is a target for the treatment of osteoporosis, arthritis, and bone metastasis. Peptidomimetics with a cyanohydrazide warhead represent a new class of highly potent CatK inhibitors; however, their binding mechanism is unknown. We investigated two model cyanohydrazide inhibitors with differently positioned warheads: an azadipeptide nitrile Gü1303 and a 3-cyano-3-aza-β-amino acid Gü2602. Crystal structures of their covalent complexes were determined with mature CatK as well as a zymogen-like activation intermediate of CatK. Binding mode analysis, together with quantum chemical calculations, revealed that the extraordinary picomolar potency of Gü2602 is entropically favoured by its conformational flexibility at the nonprimed-primed subsites boundary. Furthermore, we demonstrated by live cell imaging that cyanohydrazides effectively target mature CatK in osteosarcoma cells. Cyanohydrazides also suppressed the maturation of CatK by inhibiting the autoactivation of the CatK zymogen. Our results provide structural insights for the rational design of cyanohydrazide inhibitors of CatK as potential drugs.

Acknowledgements

The authors thank Helena Mertlíková-Kaiserová for providing U-2 OS cells. Diffraction data were collected on MX14.1 at the BESSY II electron storage ring operated by the Helmholtz-Zentrum Berlin.

Disclosure statement

No potential conflict of interest was reported by the authors.

Data availability statement

Atomic coordinates and experimental structure factors have been deposited in the Protein Data Bank with accession codes 7QBL, 7QBM, 7QBN, and 7QBO.

Additional information

Funding

This work was supported by the project ChemBioDrug CZ.02.1.01/0.0/0.0/16_019/0000729 from ERDF/OPRDE and the institutional project RVO 61388963.